No. No. components and herbs Level Mechanism on oxidative stress Mechanism on inflammation reference
1 1 13-Methylberberine A inhibiting NLRP3 inflammasome activation via autophagy induction in HUVECs Peng et al., 2020
2 2 Berberine B2 changed Ampk and Nf-κb gene expression Ma et al., 2020
3 3 Berberine B1 promoting autophagy Ke et al., 2020
4 4 Berberine B2 reduced aortic reactive oxygen species (ROS) generation and reduced the serum levels of malondialdehyde (MDA), oxidized low-density lipoprotein (ox-LDL), and interleukin-6 (IL-6) Tan et al., 2020
5 5 Berberine A activation of the AMPK/mTOR signaling pathway. Fan et al., 2015
6 6 betaine B1 Betaine could inhibit the development of atherosclerosis via anti-inflammation. Fan et al., 2008
7 7 Coptisine B2 inhibiting activation of MAPK signaling pathways and NF-κB nuclear translocation Feng et al., 2017
8 8 Dehydrocorydaline A,B2 targeting macrophage p65- and ERK1/2-mediated pathways Wen et al., 2021
9 9 Dendrobine A FKBP1A-involved autophagy ox-LDL-treated HUVECs FKBP1A-involved autophagy ox-LDL-treated HUVECs Lou et al., 2022
10 10 Leonurine A,B2 suppressed the NF-κB signaling pathway balanced NO production and inhibited NF-κB/P65 nuclear translocation Ning et al., 2020
11 11 6-gingerol B2 increased plaque formation, elevation of plasma total cholesterol, triglyceride, low-density lipoprotein cholesterin, and proinflammatory cytokines including TNF-α, IL-1β, and IL-6 Wang et al., 2018
12 12 Calycosin B2 improved autophagy through KLF2-MLKL signalling pathway modulation Ma et al., 2022
13 13 dihydromyricetin A,B2 demonstrate that endothelial miR-21-inhibited DDAH1-ADMA-eNOS-NO pathway promotes the pathogenesis of atherosclerosis which can be rescued by DMY. Yang et al., 2020
14 14 Dihydromyricetin A activating Akt and ERK1/2, which subsequently activates Nrf2/HO-1 signaling Luo et al., 2017
15 15 Flavone of Hippophae B2 upregulating CTRP6 Zhuo et al., 2019
16 16 Flavonoids A,B2 inhibiting mRNA and protein expression, inhibiting the NF-κB pathway, ameliorated ox-LDL induced macrophages-oriented foam cells formation through inducing cholesterol efflux via PPARγ-ABCA1/ABCG1 Liu et al., 2022
17 17 Formononetin C alleviates ox-LDL-induced endothelial injury in HUVECs by stimulating PPAR-γ signaling Zhang et al., 2021
18 18 Formononetin A,B2 regulation of interplay between KLF4 and SRA Ma et al., 2020
19 19 Hesperidin A alleviate BaP-induced inflammatory response by decreasing IL-1β and TNF-α expression Duan et al., 2022
20 20 Hesperidin B2 pleiotropic effects, including improvement of insulin resistance, amelioration of lipid profiles, inhibition of macrophage foam cell formation, anti-oxidative effect and anti-inflammatory action. Sun et al., 2017
21 21 2,3,5,4’-Tetrahydroxy-stilbene-2-O-β-D-glucoside B2 down-regulation of IL-6, TNF-α, VCAM-1 and MCP-1 expression in serum, and PMRP inhibited inflammation by reducing VCAM-1, ICAM-1 and CCRA expression in aortic tissue Li et al., 2019
22 22 amygdalin A,B2 MAPKs, AP-1 and NF-κB p65 signaling pathways Wang et al., 2020
23 23 polysaccharide CM1 B2 Integrated bioinformatics analysis revealed that CM1 interacted with multiple signaling pathways, including those involved in lipid metabolism, inflammatory response, oxidoreductase activity and fluid shear stress, to exert its anti-atherosclerotic effect Lin et al., 2021
24 24 Crocin A,B1 promoting M2 macrophage polarization and maybe by inhibiting NF-κB p65 nuclear translocation Li et al., 2018
25 25 Dendrobium huoshanense C. Z. Tang et S. J. Cheng polysaccharide A,B (Zebrafish) improved HCD-induced lipid deposition, oxidative stress, and inflammatory response, mainly showing that DHP significantly increased superoxide dismutase (SOD) activity, decreased plaque formation, and decreased neutrophil recruitment and the levels of total cholesterol (TC), triglyceride (TG), malondialdehyde (MDA), and reactive oxygen species (ROS) Fan et al., 2020
26 26 Gastrodin B2 attenuate the lipid deposition and foam cells on the inner membrane Liu et al., 2021
27 27 Poria cocos polysaccharides A,B2 reducing inflammatory factors and blood lipid levels Li et al., 2021
28 28 cordycepin A PI3K/Akt/eNOS signaling pathway Ku et al., 2021
29 29 Polydatin A,B2 down-regulation of PBEF and inhibition of PBEF-inducing cholesterol deposits in macrophages Huang et al., 2018
30 30 Pseudoprotodioscin A,B2 regulated adhesion molecule expression in HUVECs through an ERα/NO/NF-κB signaling pathway,exert anti-inflammatory properties through an ERα independent pathway Sun et al., 2020
31 31 5,2’-dibromo-2,4’,5’-trihydroxydiphenylmethanone A activates HMBOX1, which is an inducible protective mechanism that inhibits LPS-induced inflammation and ROS production activates HMBOX1, which is an inducible protective mechanism that inhibits LPS-induced inflammation and ROS production Yuan et al., 2019
32 32 Benzoinum A regulation of the NF-κB and caspase-9 signaling pathways Zhang et al., 2019
33 33 Bergaptol A inhibitory effects on c-Jun N-terminal kinase (JNK), P38, P65, IκBα and IκKα/β phosphorylation, and NF-κB nuclear translocation. Shen et al., 2020
34 34 Cinnamaldehyde B2 the IκB/NF-κB signaling pathway. Li et al., 2019
35 35 Curcumin A AMPK/mTOR/p70S6K pathway Zhao et al., 2021
36 36 Curcumin A interfering with the reactive oxygen species-ERK1/2 signal pathway. Zhang et al., 2020
37 37 Curcumin B2 related to LCN2 down-regulation, anti-hyperlipidemia effect as well as the inhibition of inflammation Wan et al., 2016
38 38 curcumin, Nicotinic-curcumin A reduced endothelial EVs secretion Xiang et al., 2021
39 39 Epigallocatechin gallate A enhancing SIRT1/AMPK as well as Akt/eNOS signaling pathways Pai et al., 2021
40 40 Honokiol B2 decreased reactive oxygen species level and enhanced superoxide dismutase activity. Nitric oxide level, inducible nitric oxide synthase (iNOS) expression, and aberrant activation of nuclear factor-κB pathway downregulated the expression of pro-inflammatory markers, like tumor necrosis factor-α, interleukin (IL)-6, and IL-1β Liu et al., 2020
40 40 Honokiol B2 decreased reactive oxygen species level and enhanced superoxide dismutase activity. Nitric oxide level, inducible nitric oxide synthase (iNOS) expression, and aberrant activation of nuclear factor-κB pathway downregulated the expression of pro-inflammatory markers, like tumor necrosis factor-α, interleukin (IL)-6, and IL-1β Liu et al., 2020
41 41 Dihydrotanshinone I A,B2 suppressing RIP3-mediated necroptosis of macrophage Zhao et al., 2021
42 42 Dihydrotanshinone I A,B2 inhibition of LOX-1 mediated by NOX4/NF-κB signaling pathways Zhao et al., 2016
43 43 Shikonin A,B1 inhibition of SKN on CD4+ T cell inflammatory activation Lü et al., 2020
44 44 Tanshinone II A B2 interfering with RAGE and NF‑κB activation, and downregulation of downstream inflammatory factors, including ICAM‑1, VCAM‑1, and MMP‑2, ‑3 and ‑9 Zhao et al., 2016
45 45 Tanshinone IIA A TSA represses ferroptosis via activation of NRF2 in HCAECs. He et al., 2021
46 46 Tanshinone IIA A mediating miR-130b and WNT5A Yuan et al., 2020
47 47 Tanshinone IIA A,B2 activate KLF4 and enhance autophagy as well as M2 polarization of macrophages by inhibiting miR-375 to Attenuate Atherosclerosis Chen et al., 2019
48 48 Tanshinone IIA Sodium sulfonate A,B2 The anti-oxidant, and anti-inflammation properties of STS in preventing AS is mediated by its inhibition of CLIC1 expression and membrane translocation. Zhu et al., 2017
Notes: In Level, A represents in vitro; B represents in vivo; B1 represents rats; B2 represents mice; B3 represents rabbit; C represents network pharmacology. 2. NO.1-10:Alkaloids; NO.11-20: Flavonoids; NO.21-30: Glycosides; 31-40: Phenylpropanoids; 41-48: quinones. Notes: In Level, A represents in vitro; B represents in vivo; B1 represents rats; B2 represents mice; B3 represents rabbit; C represents network pharmacology. 2. NO.1-10:Alkaloids; NO.11-20: Flavonoids; NO.21-30: Glycosides; 31-40: Phenylpropanoids; 41-48: quinones. Notes: In Level, A represents in vitro; B represents in vivo; B1 represents rats; B2 represents mice; B3 represents rabbit; C represents network pharmacology. 2. NO.1-10:Alkaloids; NO.11-20: Flavonoids; NO.21-30: Glycosides; 31-40: Phenylpropanoids; 41-48: quinones. Notes: In Level, A represents in vitro; B represents in vivo; B1 represents rats; B2 represents mice; B3 represents rabbit; C represents network pharmacology. 2. NO.1-10:Alkaloids; NO.11-20: Flavonoids; NO.21-30: Glycosides; 31-40: Phenylpropanoids; 41-48: quinones. Notes: In Level, A represents in vitro; B represents in vivo; B1 represents rats; B2 represents mice; B3 represents rabbit; C represents network pharmacology. 2. NO.1-10:Alkaloids; NO.11-20: Flavonoids; NO.21-30: Glycosides; 31-40: Phenylpropanoids; 41-48: quinones. Notes: In Level, A represents in vitro; B represents in vivo; B1 represents rats; B2 represents mice; B3 represents rabbit; C represents network pharmacology. 2. NO.1-10:Alkaloids; NO.11-20: Flavonoids; NO.21-30: Glycosides; 31-40: Phenylpropanoids; 41-48: quinones. Notes: In Level, A represents in vitro; B represents in vivo; B1 represents rats; B2 represents mice; B3 represents rabbit; C represents network pharmacology. 2. NO.1-10:Alkaloids; NO.11-20: Flavonoids; NO.21-30: Glycosides; 31-40: Phenylpropanoids; 41-48: quinones.